drugset / Trial / NCT01595880

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone

NCT01595880

Phase 1 Completed 29 enrolled LG Life Sciences
RandomizedCrossoverOpen-labelTreatment

Summary

This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of gemigliptin 50mg and metformin HCl extended release 500mg in comparison to each component administered alone in healthy male volunteers.

Timeline

Start
2014-12
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemigliptin Small molecule 50 mg Oral
Subject Metformin Small molecule 500 mg Oral

Indications

No indication recorded.